These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9149375)

  • 1. Extension of a predictive substrate model for human cytochrome P4502D6.
    de Groot MJ; Bijloo GJ; van Acker FA; Fonseca Guerra C; Snijders JG; Vermeulen NP
    Xenobiotica; 1997 Apr; 27(4):357-68. PubMed ID: 9149375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations.
    Johnson JA; Burlew BS
    Drug Metab Dispos; 1996 Mar; 24(3):350-5. PubMed ID: 8820427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.
    VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2012 Jan; 40(1):47-53. PubMed ID: 21976621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.
    Lewis DF; Eddershaw PJ; Goldfarb PS; Tarbit MH
    Xenobiotica; 1997 Apr; 27(4):319-39. PubMed ID: 9149373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression, purification, and characterization of mouse CYP2d22.
    Yu AM; Haining RL
    Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6.
    Mautz DS; Nelson WL; Shen DD
    Drug Metab Dispos; 1995 Apr; 23(4):513-7. PubMed ID: 7600921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation.
    Islam SA; Wolf CR; Lennard MS; Sternberg MJ
    Carcinogenesis; 1991 Dec; 12(12):2211-9. PubMed ID: 1747920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.
    Ellis SW; Rowland K; Ackland MJ; Rekka E; Simula AP; Lennard MS; Wolf CR; Tucker GT
    Biochem J; 1996 Jun; 316 ( Pt 2)(Pt 2):647-54. PubMed ID: 8687412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of phenylalanine at position 120 and glutamic acid at position 222 in the oxidation of chiral substrates by cytochrome P450 2D6.
    Masuda K; Tamagake K; Katsu T; Torigoe F; Saito K; Hanioka N; Yamano S; Yamamoto S; Narimatsu S
    Chirality; 2006 Feb; 18(3):167-76. PubMed ID: 16432914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double site saturation mutagenesis of the human cytochrome P450 2D6 results in regioselective steroid hydroxylation.
    Geier M; Braun A; Fladischer P; Stepniak P; Rudroff F; Hametner C; Mihovilovic MD; Glieder A
    FEBS J; 2013 Jul; 280(13):3094-108. PubMed ID: 23552177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sensitive method for determination of cytochrome P4502D6 activity in vitro using bupranolol as substrate.
    Appanna G; Tang BK; Mller R; Kalow W
    Drug Metab Dispos; 1996 Mar; 24(3):303-6. PubMed ID: 8820420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6.
    Haji-Momenian S; Rieger JM; Macdonald TL; Brown ML
    Bioorg Med Chem; 2003 Dec; 11(24):5545-54. PubMed ID: 14642599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
    Kroemer HK; Fischer C; Meese CO; Eichelbaum M
    Mol Pharmacol; 1991 Jul; 40(1):135-42. PubMed ID: 1857335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of hydrophobic parameters in identifying appropriate pose of CYP substrates in cytochromes.
    Ramesh M; Bharatam PV
    Eur J Med Chem; 2014 Jan; 71():15-23. PubMed ID: 24269512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6.
    Umeda S; Harakawa N; Yamamoto M; Ueno K
    Biol Pharm Bull; 2005 Feb; 28(2):212-6. PubMed ID: 15684471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
    Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
    Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.
    Zhou SF; Liu JP; Lai XS
    Curr Med Chem; 2009; 16(21):2661-805. PubMed ID: 19601803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine.
    Wang RW; Liu L; Cheng H
    Drug Metab Dispos; 1996 Jul; 24(7):786-91. PubMed ID: 8818577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan.
    Bonn B; Masimirembwa CM; Castagnoli N
    Drug Metab Dispos; 2010 Jan; 38(1):187-99. PubMed ID: 19797609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.